Mutant CPC Acylase for Direct 7-ACA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing two-step enzymatic process for producing 7-aminocephalosporanic acid (7-ACA) from cephalosporin C is inefficient due to low production yield caused by hydrogen peroxide attacking the substrate and reaction products, necessitating the development of a more active CPC acylase for a direct one-step process.
Innovation Solution
A mutant CPC acylase with specific amino acid substitutions in its alpha and beta-subunits, such as A11αN, G24αD, A136βT, I179βY, and H453βT, is developed to enhance enzymatic activity and stability, allowing for direct production of 7-ACA from cephalosporin C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a two-step enzymatic process is used to produce 7-ACA from CPC, then the process can proceed through intermediate GI-7-ACA, but the production yield is low due to hydrogen peroxide attacking the substrate and reaction products
Solution Approach 1:
The patent extracts and eliminates the harmful first step involving D-amino acid oxidase that generates hydrogen peroxide. By directly using CPC acylase to convert CPC to 7-ACA in a single step, the source of hydrogen peroxide is removed, preventing it from attacking the substrate and products, thus resolving the contradiction between process feasibility and production yield
Solution Approach 2:
The patent merges the two-step process into a single-step process by using CPC acylase that can directly hydrolyze CPC to produce 7-ACA. This consolidation eliminates the intermediate step that generates harmful hydrogen peroxide, thereby improving production yield while maintaining process effectiveness
2Productivity
If GI-7-ACA acylase is used to produce 7-ACA, then the enzyme can catalyze the reaction, but it shows poor activity for CPC substrate
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues in the GI-7-ACA acylase structure (e.g., K77E, R78E, R160E mutations) to alter the enzyme's catalytic properties. These parameter changes enable the enzyme to recognize and catalyze CPC substrate effectively, transforming it from a GI-7-ACA-specific enzyme to a CPC-active enzyme with high productivity
Solution Approach 2:
The patent applies local quality by making specific localized mutations at particular amino acid positions (K77, R78, R160) in the enzyme structure. These localized changes modify the active site or substrate binding region to improve CPC substrate recognition and catalysis, while maintaining the overall enzyme structure and function
3Reliability
If conventional CPC acylase is used, then the enzyme structure is simple, but the enzymatic activity and thermal stability are insufficient
Solution Approach 1:
The patent applies parameter changes by introducing multiple amino acid substitutions (e.g., A11N, G24D, A136T, I179Y, H453T mutations) to modify the enzyme's physical and chemical properties. These parameter changes enhance thermal stability and enzymatic activity without fundamentally altering the overall enzyme architecture, resolving the contradiction between simplicity and performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant CPC acylase exhibits significantly improved enzymatic activity, achieving about 5- to 21-fold higher activity and 2.5-fold higher thermal stability compared to conventional enzymes, enabling an efficient one-step process for producing 7-ACA.
Implementation Method 1
CPC acylase that catalyzes the direct production of 7-ACA from CPC
Implementation Method 2
mutant CPC acylase that has a point mutation introduced thereinto and thus exhibits improved enzymatic activity
Data Source
AI summary
Disclosed herein are a polypeptide having cephalosporin C(CPC) acylase activity and a use thereof. More specifically, a mutant CPC acylase comprising a point mutation introduced thereinto, thereby exhibiting improved enzymatic activity and/or stability, and a use of the mutant CPC acylase for producing 7-aminocephalosporanic acid (7-ACA), are provided.